Biome Australia's growth forecast for Q2 FY25

Biome Australia (ASX:BIO) has announced a forecast for its Q2 FY25 sales revenue to exceed $4.5 million. This projection marks a new record, surpassing the previous high of $4.25 million from Q1 FY25. The announcement highlights the company's continued growth in the December quarter-to-date.

Overview of Biome Australia's strategic outlook

Biome Australia is focused on microbiome health, developing and marketing innovative probiotics and complementary medicines. The company is forecasting a record quarterly sales revenue of over $4.5 million for Q2 FY25, reflecting strong growth and surpassing previous records. Biome's products, under the brand Activated Probiotics, are backed by clinical research and aim to address various health issues. The company is dedicated to educating health professionals on gut microbiota and the use of natural medicines. Despite the positive projections, Biome Australia provides caution regarding forward-looking statements, highlighting potential impacts from factors such as the Covid-19 pandemic.

Executive commentary on Biome Australia's growth projection

The announcement, approved by the Biome Australia board of directors, emphasizes the company's continued growth during the December quarter-to-date.